Loading
Common gene variants shift a person's cancer risk several-fold. A one-time genetic score could tell each person when to start breast, bowel or prostate screening.
Polygenic scores reclassify risk for breast, prostate, and colorectal cancer, and BARCODE1 showed PRS-selected prostate screening finds clinically significant disease. Propose national programmes assigning screening start age by PRS plus family history, with a pragmatic trial comparing PRS-tailored to age-based invitation.
The evidence base for setting the age at which screening starts by risk rather than by birthday. It is also a warning: the same score performs differently across ancestries, so a risk model built and validated in European cohorts will under-serve the men at highest risk.
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction, Polygenic risk score (PRS), Judge a prostate screening programme on metastatic presentation, not on incidence or mortality, The Institute of Cancer Research.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Early-onset colorectal cancer (under 50), Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Germline (hereditary) testing.